武田制药(TAK)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

TAK 武田制药

未开盘 01-30 16:00:00 EST

17.23

+0.06

+0.35%

盘后17.24

+0.01+0.06%

16:44 EST

最高17.24	最低17.05	成交量562.63万
今开17.09	昨收17.17	日振幅1.14%
总市值544.33亿	流通市值526.72亿	总股本31.59亿
成交额9,660万	换手率0.18%	流通股本30.57亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"TAK","market":"US","secType":"STK","nameCN":"武田制药","latestPrice":17.23,"timestamp":1769806800000,"preClose":17.17,"halted":0,"volume":5626273,"hourTrading":{"tag":"盘后","latestPrice":17.24,"preClose":17.23,"latestTime":"16:44 EST","volume":435503,"amount":7508039.95,"timestamp":1769809455085,"change":0.01,"changeRate":0.00058,"amplitude":0.001741},"delay":0,"changeRate":0.0034944670937681254,"floatShares":3057000000,"shares":3159188548,"eps":0.0735,"marketStatus":"未开盘","change":0.06,"latestTime":"01-30 16:00:00 EST","open":17.09,"high":17.24,"low":17.045,"amount":96603152.420184,"amplitude":0.011357,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":0.0735,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1770022800000},"marketStatusCode":0,"adr":0,"adrRate":0.5,"listingDate":1545627600000,"exchange":"NYSE","adjPreClose":17.17,"dividendRate":0.037152,"preHourTrading":{"tag":"盘前","latestPrice":16.81,"preClose":17.17,"latestTime":"09:20 EST","volume":42695,"amount":731543.47354,"timestamp":1769782813526,"change":-0.36,"changeRate":-0.020967,"amplitude":0.020967},"postHourTrading":{"tag":"盘后","latestPrice":17.24,"preClose":17.23,"latestTime":"16:44 EST","volume":435503,"amount":7508039.95,"timestamp":1769809455085,"change":0.01,"changeRate":0.00058,"amplitude":0.001741},"volumeRatio":1.4663469632640884,"impliedVol":0.2771,"impliedVolPercentile":0.2908},"requestUrl":"/m/hq/s/TAK","defaultTab":"news","newsList":[{"id":"2607061263","title":"武田制药任命刘燕为武田中国总裁","url":"https://stock-news.laohu8.com/highlight/detail?id=2607061263","media":"南方财经网","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607061263?lang=zh_cn&edition=full","pubTime":"2026-01-30 10:56","pubTimestamp":1769741778,"startTime":"0","endTime":"0","summary":"南方财经1月30日电，据“武田中国”微信公众号消息，日前，武田制药宣布任命刘燕为武田中国总裁，全面负责武田中国（包括香港、澳门地区）的整体战略和业务发展。她也同时成为新成立的武田制药国际事业部管理委员会成员。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202601303636687966.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4007","TAK"],"gpt_icon":0},{"id":"2605842904","title":"武田(TAK.US)1类新药奥博雷通片拟纳入优先审评 适用于1型发作性睡病患者","url":"https://stock-news.laohu8.com/highlight/detail?id=2605842904","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605842904?lang=zh_cn&edition=full","pubTime":"2026-01-23 14:43","pubTimestamp":1769150602,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，中国国家药监局药品审评中心官网近日公示显示，武田申报的1类新药奥博雷通片的上市申请拟纳入优先审评，适用于治疗16岁及以上1型发作性睡病患者。发作性睡病I型是一种罕见的慢性中枢神经系统疾病，由于患者的食欲素神经元大量缺失，导致大脑和脑脊液中食欲素神经肽水平低下。2025年7月，武田宣布奥博雷通片的两项针对NT1的3期研究达到所有主要和次要终点。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1396593.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4007","TAK"],"gpt_icon":0},{"id":"1158037503","title":"财报前瞻｜武田制药本季度营收预计小幅增长，机构观点偏谨慎","url":"https://stock-news.laohu8.com/highlight/detail?id=1158037503","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1158037503?lang=zh_cn&edition=full","pubTime":"2026-01-22 10:22","pubTimestamp":1769048526,"startTime":"0","endTime":"0","summary":"武田制药将于2026年01月29日发布最新季度财报，市场聚焦营收改善与利润恢复节奏，关注核心管线商业化对利润率的影响。市场一致预期本季度武田制药总收入约为1149.65亿美元，同比增长6.05%，预计EBIT为105.89亿美元，同比增长174.79%；公司上个季度财报口径显示对本季度的收入与利润预期以改善为主，但净利润和每股收益的预测未披露，毛利率与净利率的季度预测数据暂无。近期机构对武田制药的观点偏谨慎，看空比例更高。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"财报前瞻｜武田制药本季度营收预计小幅增长，机构观点偏谨慎","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TAK"],"gpt_icon":0},{"id":"2603683739","title":"武田制药(TAK.US)1类新药“奥博雷通片”在中国申报上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2603683739","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603683739?lang=zh_cn&edition=full","pubTime":"2026-01-16 15:32","pubTimestamp":1768548757,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，1月16日，中国国家药监局药品审评中心官网最新公示显示，武田制药申报的1类新药奥博雷通片上市申请获得受理。该产品此前已经被CDE纳入突破性治疗品种，针对1型发作性睡病适应症。其针对NT1适应症的两项3期关键性研究已经达到所有主要和次要终点。在刚刚结束的2026年JPM大会上，武田披露该产品预计于2026年下半年获监管机构批准上市。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1393785.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"武田制药(TAK.US)1类新药“奥博雷通片”在中国申报上市","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4007","TAK"],"gpt_icon":0},{"id":"2593637123","title":"产业新闻丨武田公布TYK2抑制剂治疗银屑病3期临床研究积极结果","url":"https://stock-news.laohu8.com/highlight/detail?id=2593637123","media":"医药观澜","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593637123?lang=zh_cn&edition=full","pubTime":"2025-12-20 12:12","pubTimestamp":1766203940,"startTime":"0","endTime":"0","summary":"武田制药计划在即将举行的医学会议上公布研究数据，并计划自2026财年向美国FDA及其他监管机构递交新药上市申请。Zasocitinib是一款在研的新一代高选择性口服TYK2抑制剂，可在24小时内持续抑制IL-23以及其他驱动疾病进展的核心免疫通路。武田目前正开展Zasocitinib与在斑块状银屑病中的研究，并推进其在银屑病关节炎中的3期临床试验。Zasocitinib目前仍处于研究阶段，尚未获得任何监管机构的上市批准。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251220121640a46276e2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251220121640a46276e2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","TAK"],"gpt_icon":0},{"id":"2592180118","title":"产业新闻 | 诺和诺德向FDA递交CagriSema上市申请；武田下一代小分子疗法达两项3期试验双主要终点……","url":"https://stock-news.laohu8.com/highlight/detail?id=2592180118","media":"药明康德","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592180118?lang=zh_cn&edition=full","pubTime":"2025-12-19 07:32","pubTimestamp":1766100744,"startTime":"0","endTime":"0","summary":"诺和诺德向FDA递交CagriSema上市申请诺和诺德今日宣布，已向美国FDA递交CagriSema的新药申请。根据新闻稿，若获批，CagriSema将成为首个可注射GLP-1受体激动剂+胰淀素类似物的联合治疗方案。而在假设所有患者均持续用药的前提下，CagriSema组在第68周的体重下降幅度为22.7%，安慰剂组为2.3%。此外，CagriSema组有91.9%的受试者体重下降幅度达到或超过5%，而安慰剂组为31.5%。两项试验均为随机、多中心、双盲设计，并设置安慰剂及活性药物对照。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251219073557a6b454f6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251219073557a6b454f6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IE00BKVL7J92.USD","NVO","BK4585","IE00BZ1G4Q59.USD","BK4599","TAK","LU1093756325.SGD","BK4588","BK4532","BK4007","LU0154236417.USD","LU1093756168.USD"],"gpt_icon":1},{"id":"2592909774","title":"武田制药公布银屑病新药临床研究结果 每日一次口服方案有望实现皮损清除","url":"https://stock-news.laohu8.com/highlight/detail?id=2592909774","media":"中国网财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592909774?lang=zh_cn&edition=full","pubTime":"2025-12-18 21:31","pubTimestamp":1766064673,"startTime":"0","endTime":"0","summary":"中国网财经12月18日讯武田制药今日宣布，其针对中重度斑块状银屑病(PsO)成人患者的新一代、高选择性口服酪氨酸激酶2(TYK2)抑制剂Zasocitinib(TAK-279)在两项关键性3期、随机、多中心、双盲、安慰剂与活性对照研究中取得积极的主要结果。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202512183595727826.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512183595727826.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["TAK","BK4007"],"gpt_icon":0},{"id":"2589685310","title":"信达生物(01801)完成与武田制药的全球战略合作及根据一般授权发行691.38万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2589685310","media":"智通财经","labels":["shareholding","corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589685310?lang=zh_cn&edition=full","pubTime":"2025-12-05 07:15","pubTimestamp":1764890112,"startTime":"0","endTime":"0","summary":"智通财经APP讯，信达生物 发布公告，内容有关信达生物与武田制药达成全球战略合作，许可、选择权及合作协议及股份发行协议各自的所有先决条件均已达成或获豁免(如适用)。于股份发行协议完成后，公司向认购人配发及发行691.38万股股份，占发行认购股份后公司已发行股本的约0.40%。配发及发行认购股份的所得款项总额约为7.78亿港元，而所得款项净额约为7.77亿港元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1377949.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1583","LU0455707207.USD","BK1589","LU2242644610.SGD","LU1969619763.USD","LU2097828631.EUR","LU0502904849.HKD","BK4007","LU2488822045.USD","LU2097828714.EUR","LU2097828805.USD","01801","LU2097828474.EUR","TAK","HK0000165453.HKD","BK1161","LU2328871848.SGD","LU2097828557.USD"],"gpt_icon":0},{"id":"2584786920","title":"Neurocrine公司抑郁症新药II期研究未达主要终点","url":"https://stock-news.laohu8.com/highlight/detail?id=2584786920","media":"GPLP犀牛财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2584786920?lang=zh_cn&edition=full","pubTime":"2025-11-19 19:34","pubTimestamp":1763552095,"startTime":"0","endTime":"0","summary":"近日，神经科学领域的生物制药公司Neurocrine Biosciences宣布，在研抑郁症药物NBI-1070770的II期临床试验未能达到预设主要终点，这一结果也为其与武田制药的合作研发项目再添波折。该药物的研发权益源于2020年Neurocrine与武田的合作，当时武田授予其七个在研药物的独家许可，NBI-1070770便是其中针对抑郁症的核心资产之一。Neurocrine在声明中指出，NBI-1070770整体耐受性良好，试验期间未报告严重不良事件，但所有剂量组均未在主要终点上展现出优于安慰剂的统计学差异。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251119193517950e580f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251119193517950e580f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["TAK","BK4007"],"gpt_icon":0},{"id":"2581285230","title":"医药行业 “砍单潮” 来袭，研发管线迎大调整","url":"https://stock-news.laohu8.com/highlight/detail?id=2581285230","media":"制药网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2581285230?lang=zh_cn&edition=full","pubTime":"2025-11-08 16:27","pubTimestamp":1762590458,"startTime":"0","endTime":"0","summary":"11月医药行业 “砍单潮” 打破了研发领域的平静。此次终止的项目中，“数据未达预期” 成为高频原因，暴露出前沿疗法的研发痛点。阿斯利康的 MASH 药物 AZD2693 则在 2b 期试验中因 “疗效不佳” 被叫停，成为该领域研发折戟的又一案例。阿斯利康的调整同样遵循 “优先级法则”，终止 KRAS G12D 抑制剂 AZD0022 等项目，正是为了聚焦自主研发的下一代 ADC 等核心管线。辉瑞仍保有 101 个在研项目，阿斯利康在 ADC 领域的自主研发持续加码。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251108162941a6eaa43d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251108162941a6eaa43d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4550","LU1023059063.AUD","PFE","BK4599","IE00BKVL7J92.USD","IE00BZ1G4Q59.USD","LU0154236417.USD","SG9999001176.USD","LU0868494617.USD","IE00B19Z3581.USD","BK4007","IE00BLSP4239.USD","LU0321505868.SGD","IE00B19Z3B42.SGD","LU0225771236.USD","LU1093756325.SGD","IE00BBT3K403.USD","LU0321505439.SGD","SG9999002224.SGD","LU0225284248.USD","LU0234572021.USD","NVO","LU1894683264.USD","SG9999001176.SGD","LU0985481810.HKD","LU1894683348.USD","IE000M9KFDE8.USD","LU0170899867.USD","SG9999002232.USD","LU1883839398.USD","BK4581","SG9999011175.SGD","LU0456855351.SGD","LU1066051498.USD","BK4568","SG9999013999.USD","BK4534","LU0289739699.SGD","LU1057294990.SGD","TAK","LU0122379950.USD","SGXZ57979304.SGD","BK4532","BK4533","IE0002270589.USD","IE00BLSP4452.SGD","BK4585","BK4592","LU1093756168.USD","BK4588","LU0306806265.USD"],"gpt_icon":1},{"id":"2580746447","title":"三巨头同日终止6项临床项目！","url":"https://stock-news.laohu8.com/highlight/detail?id=2580746447","media":"新浪财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2580746447?lang=zh_cn&edition=full","pubTime":"2025-10-31 21:01","pubTimestamp":1761915689,"startTime":"0","endTime":"0","summary":"百时美施贵宝 、 礼来 、武田三大跨国药企同步宣布终止6项临床阶段项目，覆盖肿瘤、慢性疼痛、神经疾病等热门治疗领域。BMS此次调整涉及两项关键战略资产，均与此前大额投资布局相关。不过礼来强调与旭化成的licensing 协议仍有效，目前正评估该药物用于其他适应症的可能性。值得注意的是，P2X7靶点此前已多次折戟，GSK、 阿斯利康 等企业均曾因数据或疗效问题终止相关项目。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251031211741a4801ac9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251031211741a4801ac9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2125909759.SGD","LU2125909916.SGD","BMS","TAK","LU2211815571.USD","LU1815336091.USD","LU0053671581.USD","BK4007","LU1923622291.USD","LU0728928796.USD","BK4143","MSA","LU0757428866.USD"],"gpt_icon":0},{"id":"2577932375","title":"招银国际：微升信达生物(01801)目标价至110.62港元 与武田制药达成战略合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2577932375","media":"智通财经网","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2577932375?lang=zh_cn&edition=full","pubTime":"2025-10-24 15:49","pubTimestamp":1761292155,"startTime":"0","endTime":"0","summary":"截至2025年6月，信达生物资金状况稳健，现金余额为21亿美元，为其全球野心提供稳固财务基础。","market":"hk","thumbnail":"https://img.zhitongcaijing.com/image/20251024/20251024154953_76475.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20251024/20251024154953_76475.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1359301.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["01801","TAK"],"gpt_icon":0},{"id":"2577374117","title":"海通国际：信达生物(01801)与武田制药达成114亿美元交易 合作商业化值得期待","url":"https://stock-news.laohu8.com/highlight/detail?id=2577374117","media":"智通财经网","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2577374117?lang=zh_cn&edition=full","pubTime":"2025-10-23 17:00","pubTimestamp":1761210001,"startTime":"0","endTime":"0","summary":"该行看好IBI363作为下一代肿瘤基石疗法的潜力，其有望持续拓展治疗边界，未来市场空间巨大。","market":"us","thumbnail":"https://img.zhitongcaijing.com/image/20251023/20251023152608_45289.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20251023/20251023152608_45289.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1358731.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK1161","01801","TAK","LU2097828714.EUR","LU2488822045.USD","LU2097828474.EUR","LU2097828557.USD","LU1969619763.USD","LU2328871848.SGD","BK1583","BK1589","LU2097828805.USD","LU2242644610.SGD","LU0502904849.HKD","LU0455707207.USD","BK4007","LU2097828631.EUR"],"gpt_icon":0},{"id":"2577751343","title":"里昂：信达生物(01801)与武田制药合作对推进产品研发正面 目标价升至120.1港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2577751343","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2577751343?lang=zh_cn&edition=full","pubTime":"2025-10-23 15:46","pubTimestamp":1761205597,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，里昂发布研报称，信达生物与日本武田制药宣布达成全球战略合作，双方将全球范围内共同开发新一代IO基石疗法IBI363，并就在研项目IBI343及IBI3001达成授权合作。计入这次合作的影响，里昂将信达生物2026财年销售额及净利润预测上调48.5%及172%，2027财年净利预测上调1.5%，目标价从111.4港元上调至120.1港元，维持“跑赢大市”评级。里昂认为此合作对于信达的全球化布局及产品开发进展属正面，尤其可推动核心项目IBI363发展。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1358638.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["TAK","01801"],"gpt_icon":0},{"id":"2577320674","title":"武田制药、诺和诺德终止 细胞疗法迎来“淘汰赛”｜医药观察","url":"https://stock-news.laohu8.com/highlight/detail?id=2577320674","media":"首席消费官","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2577320674?lang=zh_cn&edition=full","pubTime":"2025-10-23 09:41","pubTimestamp":1761183680,"startTime":"0","endTime":"0","summary":"武田制药、诺和诺德终止  细胞疗法迎来“淘汰赛”导语：曾经备受资本追捧的细胞疗法领域，开始迎来一场不可避免的大洗牌。2025年秋，全球生物医药领域接连传来震动性消息，武田制药宣布全面停止细胞疗法相关业务，彻底告别CGT赛道。紧随其后，诺和诺德终止所有细胞疗法研发项目，近250名相关部门员工面临失业。对于武田、诺和诺德等巨头而言，撤退并非否定细胞疗法的价值，而是基于“资源聚焦”的理性决策。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251023104108a46f9925&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251023104108a46f9925&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4588","LU0154236417.USD","02171","LU1093756325.SGD","BK4585","BK4599","NVO","LU1093756168.USD","IE00BZ1G4Q59.USD","TAK","IE00BKVL7J92.USD","BK4532","BK4007"],"gpt_icon":1},{"id":"2577961303","title":"港股公告掘金 | 信达生物与武田制药达成全球战略合作及根据一般授权发行股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2577961303","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2577961303?lang=zh_cn&edition=full","pubTime":"2025-10-22 23:00","pubTimestamp":1761145247,"startTime":"0","endTime":"0","summary":"【重大事项】信达生物(01801)与武田制药达成全球战略合作及根据一般授权发行股份中国联通(00762)拟分拆智网科技至深交所创业板上市老铺黄金(06181)拟折让约4.50%配售371.18万股新H股 净筹约27.07亿港元信利国际(00732)拟以公开投标方式收购信利仁寿的共计约11.43%股权轩竹生物-B(02575)：吡洛西利一线治疗HR+/HER2-晚期乳腺癌临床III期研究数据于202","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1358440.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2242644610.SGD","BK1561","LU2097828714.EUR","BK1506","BK1583","LU2328871848.SGD","BK1544","TAK","BK1227","BK1123","LU2488822045.USD","00762","LU0502904849.HKD","01801","BK1161","SGXZ90724238.SGD","LU2097828805.USD","LU1969619763.USD","LU2097828474.EUR","SG9999002463.SGD","BK1536","SG9999001051.SGD","LU0455707207.USD","LU2097828631.EUR","BK1589","LU2097828557.USD","00293","BK1133","BK4007"],"gpt_icon":1},{"id":"2577626350","title":"三款国产抗癌药卖出天价BD！信达生物114亿美元出海，深度绑定武田制药闯关美国市场","url":"https://stock-news.laohu8.com/highlight/detail?id=2577626350","media":"时代财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2577626350?lang=zh_cn&edition=full","pubTime":"2025-10-22 17:56","pubTimestamp":1761126969,"startTime":"0","endTime":"0","summary":"中国创新药的BD（商务拓展）交易天花板被信达生物（01801.HK）打破。10月22日，信达生物宣布，其与武田制药就IBI363、IBI343、IBI3001三款核心抗癌疗法达成全球合作。根据协议，三款药物将以不同的形式达成合作。其中，新一代IO基石疗法IBI363（PD-1/IL-2α-bias）与武田制药达成共同开发协议，将在全球范围内共同开发，并在美国共同商业化。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202510223541233079.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU2242644610.SGD","BK1583","LU2488822045.USD","LU2097828557.USD","LU2328871848.SGD","LU0502904849.HKD","LU2097828631.EUR","LU2097828714.EUR","LU2097828474.EUR","BK1161","LU0455707207.USD","LU1969619763.USD","LU2097828805.USD","TAK","BK4007","BK1589","01801"],"gpt_icon":0},{"id":"2577886380","title":"围绕IBI363与IBI343，信达生物与武田制药达成超百亿美元合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2577886380","media":"财中社","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2577886380?lang=zh_cn&edition=full","pubTime":"2025-10-22 09:44","pubTimestamp":1761097468,"startTime":"0","endTime":"0","summary":"10月22日，信达生物（01801）发布公告，与武田制药达成全球战略合作，旨在加速推进信达生物新一代IO及ADC疗法开发。本次合作包括两款后期在研疗法IBI363及IBI343，以及一款早期研发项目IBI3001的选择权。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202510223540870141.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU2488822045.USD","BK4007","LU2328871848.SGD","TAK","LU0502904849.HKD","LU2097828805.USD","BK1583","LU1969619763.USD","LU2097828631.EUR","LU2097828474.EUR","01801","LU2097828557.USD","LU2242644610.SGD","BK1589","BK1161","LU2097828714.EUR","LU0455707207.USD"],"gpt_icon":0},{"id":"2577389518","title":"信达生物(01801)与武田制药达成全球战略合作及根据一般授权发行股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2577389518","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2577389518?lang=zh_cn&edition=full","pubTime":"2025-10-22 07:54","pubTimestamp":1761090890,"startTime":"0","endTime":"0","summary":"智通财经APP讯，信达生物 发布公告，于2025年10月22日，信达生物与武田制药达成全球战略合作，旨在加速推进信达生物新一代IO及ADC疗法开发，拓展全球市场价值。认购股份将根据一般授权配发及发行。董事认为，与武田制药拟进行的战略合作是推动本公司长远发展的重要一步，并有助于实现本公司“成长为国际一流的生物制药企业”的使命。溢价股权投资表明武田制药认可本公司的长期增长潜力。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1357865.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["TAK","LU2328871848.SGD","LU2097828805.USD","BK1161","LU2488822045.USD","LU1969619763.USD","LU0502904849.HKD","BK1589","LU2097828557.USD","LU2097828631.EUR","01801","LU2242644610.SGD","LU0455707207.USD","LU2097828714.EUR","BK1583","LU2097828474.EUR","BK4007"],"gpt_icon":0},{"id":"2575298988","title":"美国生物技术公司Nabla Bio与日本武田制药扩大AI药物设计合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2575298988","media":"环球市场播报","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2575298988?lang=zh_cn&edition=full","pubTime":"2025-10-14 17:23","pubTimestamp":1760433780,"startTime":"0","endTime":"0","summary":"美国生物技术公司 Nabla Bio 于周二宣布，已与日本制药企业武田制药签署第二项重大研究合作协议，双方将深化人工智能应用，以加速药物研发进程。　　Nabla Bio 表示，将运用其自主研发的 AI 平台 “联合原子模型”，为武田制药早期研发管线设计基于蛋白质的治疗药物。　　Nabla Bio 预计，其借助 AI 设计的分子药物，将在 1 至 2 年内进入首次人体试验阶段并获取相关数据。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2025-10-14/doc-inftwafn2880003.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["TAK","BK4007"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.takeda.com","stockEarnings":[{"period":"1week","weight":0.0577},{"period":"1month","weight":0.1052},{"period":"3month","weight":0.282},{"period":"6month","weight":0.2168},{"period":"1year","weight":0.2577},{"period":"ytd","weight":0.1052}],"compareEarnings":[{"period":"1week","weight":0.004},{"period":"1month","weight":0.0147},{"period":"3month","weight":0.0145},{"period":"6month","weight":0.113},{"period":"1year","weight":0.1437},{"period":"ytd","weight":0.0147}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Takeda Pharmaceutical Company Limited是一家在日本注册成立的上市公司成立于1925年1月12日。该公司及其子公司是一家主要的全球制药集团，从事医药产品、非处方药和准药品消费品以及其他医疗保健产品的研究、开发、制造和营销。武田的主要医药产品包括以下治疗领域的药物：胃肠病学、肿瘤学和神经科学。","yearOnYearQuotes":[{"month":1,"riseRate":0.75,"avgChangeRate":0.042998},{"month":2,"riseRate":0.428571,"avgChangeRate":-0.007122},{"month":3,"riseRate":0.571429,"avgChangeRate":-0.002095},{"month":4,"riseRate":0.571429,"avgChangeRate":-0.002036},{"month":5,"riseRate":0.428571,"avgChangeRate":-0.001695},{"month":6,"riseRate":0.285714,"avgChangeRate":-0.012671},{"month":7,"riseRate":0.428571,"avgChangeRate":-0.00545},{"month":8,"riseRate":0.714286,"avgChangeRate":0.014511},{"month":9,"riseRate":0.285714,"avgChangeRate":-0.022057},{"month":10,"riseRate":0.285714,"avgChangeRate":-0.062844},{"month":11,"riseRate":0.714286,"avgChangeRate":0.063577},{"month":12,"riseRate":0.714286,"avgChangeRate":0.019204}],"exchange":"NYSE","name":"武田制药","nameEN":"Takeda Pharmaceutical Co Ltd"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"武田制药(TAK)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供武田制药(TAK)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"武田制药,TAK,武田制药股票,武田制药股票老虎,武田制药股票老虎国际,武田制药行情,武田制药股票行情,武田制药股价,武田制药股市,武田制药股票价格,武田制药股票交易,武田制药股票购买,武田制药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"武田制药(TAK)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供武田制药(TAK)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}